Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huber gets API production approval
Huber said that the license granted by California’s Department of Public Health, Food and Drug Branch represents a milestone for the continued development of Huber’s Health & Nutrition
Huber said that the license granted by California’s Department of Public Health, Food and Drug Branch represents a milestone for the continued development of Huber’s Health & Nutrition
The objective of this extension study was to assess the long-term (24 month) efficacy and safety of two doses of Safinamide (50mg and 100mg once daily tablets) as
Takeda said that TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20
Par Pharma has posted a net income of $30.53m for the third quarter 2010, compared to $26.34m for the comparable period in 2009. Operating income was $40.61m, compared
Egberts will replace current CEO Simon Sturge, who will leave the company as per 1 January 2011. Egberts is expected to immediately start working together with Sturge until
Affymax CEO Arlene Morris said that the Therapeutic Discovery Project empowers small biotech companies, like Affymax, by providing needed capital to support breakthrough medical discovery, innovation and job
The grants are related to four of Lipocine’s development programs in hormone replacement therapy, high-risk pregnancy support, oral treatment of progressive glioblastoma multiforme and opioid resistant cough in
The grant, which targets therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or to treat chronic
Perrigo has posted a net income of $74.38m for the first quarter 2010, or $0.80 per diluted share, compared to $51.86m, or $0.56 per diluted share, for the
This pharmaceutical optimisation followed the demonstration of safety and the presumption of efficacy of oral doses as high as 4mg of inecalcitol per day in a Phase IIa